Company
Novartis
Official Name: Novartis AG
Headquarters: Basel, Switzerland
Founded: March 1996
Employees: 104,323
Market Cap
CHF173.38 Billion
CHF as of Jan. 1, 2025
US$191.44 Billion
Company Description
Novartis AG is a global healthcare company that researches, develops, manufactures, and markets healthcare products. It operates through two segments: Innovative Medicines, offering prescription drugs across various therapeutic areas, and Sandoz, which develops, manufactures, and markets finished dosage form medicines, and provides active pharmaceutical ingredients, biosimilars, and biotechnology manufacturing services. Novartis collaborates with various entities to enhance its product offerings.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CHF44.59 B |
| EBITDA | CHF19.71 B |
| Gross Profit TTM | CHF34.19 B |
| Profit Margin | 35.25% |
| Operating Margin | 33.47% |
| Quarterly Revenue Growth | 8.90% |
Stocks & Indices
Novartis AG has the following listings and related stock indices.
Stock: SIX: NOVN wb_incandescent
Stock: BCBA: NVS wb_incandescent
Stock: Bovespa: N1VS34 wb_incandescent
Stock: NYSE: NVS wb_incandescent
Stock: OTC: NVSEF wb_incandescent
Stock: SIX: NOVNEE wb_incandescent
Stock: FSX: NOTA wb_incandescent
Product & Services
Pharmaceutical Research and Development, Pharmaceutical Manufacturing, Prescription Medicines, Ophthalmology, Neuroscience, Immunology, Hepatology, Dermatology, Respiratory Medicine, Cardiovascular Medicine, Renal and Metabolism Medicine, Generics, Biosimilars, Biotechnology Manufacturing Services
Key People
Founder(s): Johann Rudolf Alexander Clavel
Vasant Narasimhan (CEO)